Efforts to identify and evaluate next-generation therapeutics for pediatric brain tumors are easily stymied by the quality and availability of laboratory models for research. To address this issue, scientists at St. Jude Children’s Research Hospital developed patient-derived tumor organoids and tumor organoid xenografts that accurately reflect the biologic underpinnings of embryonal brain tumors.